BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER

By WebmasterSeptember 16, 2014November 1st, 2024No Comments

Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER
Read more here

Previous PostOptofluidics Awarded NIH Phase II SBIR
Next PostHealthQx Partners with Leader in Value-based Payment Reform

Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostOptofluidics Awarded NIH Phase II SBIR

Next PostHealthQx Partners with Leader in Value-based Payment Reform